Chengdu Kanghua Biological Products (300841) — Net Asset Quality Index
Chengdu Kanghua Biological Products (300841) has a Net Asset Quality Index of 89.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.94 Billion minus total liabilities of CN¥430.82 Million yields net assets of CN¥3.51 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See operational self-sufficiency of Chengdu Kanghua Biological Products to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Chengdu Kanghua Biological Products Net Asset Quality Index Over Time (2015–2024)
This chart shows how Chengdu Kanghua Biological Products's Net Asset Quality Index has evolved across 10 annual periods from 2015 to 2024. As of September 2025, the index stands at 89.1%, representing net assets of CN¥3.51 Billion against total assets of CN¥3.94 Billion CNY. Explore Chengdu Kanghua Biological Products (300841) cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Chengdu Kanghua Biological Products (2015–2024)
The table below presents the year-by-year Net Asset Quality Index for Chengdu Kanghua Biological Products from 2015 to 2024, covering 10 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Chengdu Kanghua Biological Products stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 85.6% | CN¥3.45 Billion | CN¥4.03 Billion | CN¥580.07 Million | ▲ +2.1 pp |
| 2023 | 83.5% | CN¥3.51 Billion | CN¥4.21 Billion | CN¥695.22 Million | ▲ +0.6 pp |
| 2022 | 82.9% | CN¥3.08 Billion | CN¥3.71 Billion | CN¥635.40 Million | ▼ -5.6 pp |
| 2021 | 88.5% | CN¥2.67 Billion | CN¥3.02 Billion | CN¥347.74 Million | ▼ -3.5 pp |
| 2020 | 91.9% | CN¥1.97 Billion | CN¥2.15 Billion | CN¥173.24 Million | ▲ +8.5 pp |
| 2019 | 83.4% | CN¥574.65 Million | CN¥689.14 Million | CN¥114.49 Million | ▲ +7.7 pp |
| 2018 | 75.6% | CN¥367.70 Million | CN¥486.07 Million | CN¥118.37 Million | ▲ +7.1 pp |
| 2017 | 68.6% | CN¥188.37 Million | CN¥274.74 Million | CN¥86.38 Million | ▲ +116.4 pp |
| 2016 | -47.9% | CN¥-96.21 Million | CN¥201.01 Million | CN¥297.23 Million | ▲ +12.7 pp |
| 2015 | -60.6% | CN¥-102.87 Million | CN¥169.74 Million | CN¥272.61 Million | — |